NUVL Nuvalent, Inc.

NEUTRAL Impact: 3/10 Insider Cluster (2 insiders)
Horizon weeks Filed Jun 10, 2026 Processed 2d 19h ago
Insider cluster: 2 insiders, $1.2M total

Price Chart

Loading chart...

Executive Summary

Nuvalent CEO James Porter exercised 30,000 options at $18.93/share and sold 12,495 shares on the open market for $1.1M, while CFO Alexandra Balcom sold 960 shares for $91K. These sales occurred just one day after the announcement of GSK's $10.6B acquisition of Nuvalent at $124/share, suggesting the CEO's sale was likely pre-planned (option exercise + sell-to-cover) rather than a bearish signal. The cluster is trivial relative to the $9.7B market cap (0.01%) and is overshadowed by the transformative acquisition premium.

Key Financial Metrics

Direction
selling
Total Value
$1.2M
Insiders
2

Actionable Insight

The insider sales are immaterial and likely pre-planned. The GSK acquisition at $124/share is the dominant event — traders should focus on deal closing risks (regulatory approval, tender condition) rather than this insider activity. Monitor for any insider purchases or unusual option activity that might signal deal skepticism.

Key Facts

  • CEO Porter exercised 30,000 options at $18.93/share ($567,900) and sold 12,495 shares at $87.97 ($1.1M) on June 8, 2026
  • CFO Balcom sold 960 shares at $94.87 ($91K) on June 1, 2026
  • Total insider sales of $1.19M represent ~0.01% of Nuvalent's $9.7B market cap
  • GSK acquisition at $124/share (43% premium to recent price) was announced June 9, 2026 — one day after the CEO's sale
  • The CEO's option exercise and sale pattern is consistent with routine tax-related selling, not informed bearishness

Financial Impact

Insider sales of $1.19M are trivial relative to $9.7B market cap (0.01%)

dilution

Risk Factors

  • Insider sales could be misinterpreted as bearish by retail traders unaware of the acquisition context
  • CEO's option exercise adds 30,000 shares to the float, but this is negligible
  • The acquisition may face regulatory hurdles or competing bids

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NUVL-1781123508183
13 reports for NUVL
Performance horizon
33% Hit rate 2 of 6 directional calls best @ T+1▲ +2.73%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
Type Now
Jun 11, 2026
1d ago
Insider Cluster
NEUTRAL ★ 2/10
$123.40 awaiting T+20awaiting T+20$123.25 (−0.12%)
Jun 10, 2026
2d ago
Insider Cluster
NEUTRAL ★ 3/10
$123.40 awaiting T+20awaiting T+20$123.25 (−0.12%)
Jun 9, 2026
4d ago
8-K
BULLISH ★ 8/10
$122.92 awaiting T+20awaiting T+20$123.25 (+0.27%)
May 7, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$102.40 $90.18▼ −11.93%▼ −15.07%$123.25 (+20.36%)
Apr 29, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $107.38▲ +8.36%▲ +2.90%$123.25 (+24.37%)
Apr 7, 2026
9w ago
8-K
BULLISH ★ 7/10
$102.25 $102.62▲ +0.36%▼ −9.42%$123.25 (+20.54%)
Apr 6, 2026
9w ago
Insider Cluster
BEARISH ★ 6/10
$103.71 $102.62▲ +1.05%▲ +10.03%$123.25 (−18.84%)
Mar 30, 2026
10w ago
Insider Cluster
BEARISH ★ 7/10
$96.72 $101.94▼ −5.40%▲ +7.20%$123.25 (−27.43%)
Mar 26, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$98.06 $104.50▲ +6.57%▼ −4.10%$123.25 (+25.69%)
Mar 25, 2026
11w ago
Insider Cluster
BEARISH ★ 7/10
$98.00 $108.02▼ −10.22%▼ −2.36%$123.25 (−25.77%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (45h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access